1 / 8

Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS)

Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS). AHA, 2008. For UA/NSTEMI pts that are treated with an invasive strategy, the timing of catheterization has not been rigorously investigated. Background. TIMACS: Methods.

holland
Télécharger la présentation

Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008

  2. For UA/NSTEMI pts that are treated with an invasive strategy, the timing of catheterization has not been rigorously investigated. Background

  3. TIMACS: Methods • Pts with UA/NSTEMI randomized to early invasive strategy (angiography within 24 hrs) or delayed invasive strategy (angiography any time after 36 hrs). • Primary endpoint: - composite of death, new MI, or CVA at 6 months. • Secondary endpoints: - death, new MI, or refractory ischemia - death, new MI, CVA, refractory ischemia, repeat revascularization - CVA

  4. 3,031 pts enrolled (1,593 pts in early invasive strategy – median time to cath 14 hrs; 1,438 pts in delayed invasive strategy – median time to cath 50 hrs). • Mean age 65.4 yrs; 35% females. • 77% pts with NSTEMI • 27% pts with DM; 20% pts with h/o MI • ASA (98%), Thienopyridine (87%), BBlockers (86.9%), Statins (85%), LMWH (64.3%), UFH (24.6%), Fondaparinux (41.5%, part of the pts were enrolled in OASIS), gp2b/3a (23%), bivalirudin (0.5%). • 25% pts crossed from delayed to early strategy (refractory ischemia, new MI or instability). 12% crossed from early to delayed strategy.

  5. Primary and secondary outcomes in TIMACS hazard ratio (95% CI), early vs delayed strategies *Primary end point Mehta SR et al. American Heart Association 2008 Scientific Sessions; November 10, 2008; New Orleans, LA.

  6. Rates of death, MI, or stroke within six months according to GRACE risk level and HR (95% CI), early vs delayed *Low/intermediate risk=GRACE score <140 High risk=GRACE score >140 Mehta SR et al. American Heart Association 2008 Scientific Sessions; November 10, 2008; New Orleans, LA.

  7. GRACE score – predicts the risk of in-hospital mortality Arch Intern Med 2003;163:2345-2353

  8. TIMACS: Conclusions • Early invasive strategy in pts with UA/NSTEMI is not superior to delayed invasive strategy with regard to the composite of death, new MI and CVA at 6 months, unless pt is high risk (as assessed by the GRACE risk model). • Early invasive strategy is superior in reducing the incidence of refractory angina without increasing the risk of bleeding. • Early invasive strategy can be implemented very early after pt’s admission – no benefit in “cooling pt off”.

More Related